It has been also described that NF-κB activation in glioblastoma cells by RSL3 treatment leads to an increase of lipid ROS and a reduction of anti-ferroptosis proteins such as GPX4, ATF4, and SLC7A11 [342]. The gene discussed is SLC7A11; the disease is glioblastoma.